-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tislelizumab in Muscle Invasive Bladder Cancer (MIBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tislelizumab in Muscle Invasive Bladder Cancer (MIBC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tislelizumab in Muscle Invasive Bladder Cancer (MIBC) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tislelizumab in Urethral Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tislelizumab in Urethral Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tislelizumab in Urethral Cancer Drug Details: Tislelizumab (Baizean, Tevimbra) is a...
-
Product Insights
Osteoporosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Osteoporosis - Drugs In Development, 2023’, provides an overview of the Osteoporosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Osteoporosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Plasma Cell Neoplasm – Drugs In Development, 2023
Global Markets Direct’s, ‘Plasma Cell Neoplasm - Drugs In Development, 2023’, provides an overview of the Plasma Cell Neoplasm pipeline landscape. The report provides comprehensive information on the therapeutics under development for Plasma Cell Neoplasm, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Hematological Disorders Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
Hematological Disorders Pipeline Market Report Overview The hematological disorders pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the territories wherein the clinical trials are in progress, the regulatory paths followed by the trials, and the companies associated with the trials. Key Segments ·       Hemostasis Tests ·       Coagulation Analyzers ·       Special Coagulation Tests ·       Hematology Tests ·       General Coagulation Tests Key...
-
Product Insights
Auto-Immune Diseases Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
Auto-immune diseases Pipeline Market Report Overview Auto-immune diseases are used for detection of autoimmune disorder by identifying auto-antibodies in the patient’s test sample. The auto-immune diseases pipeline market research report provides a comprehensive understanding of the pipeline products and their comparative analysis at various stages of development. The report also includes information about the territories wherein the clinical trials are in progress, the regulatory paths followed by the trials, and the companies associated with the trials. Key Territories ·       The...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HH-2853 in Natural Killer Cell Lymphomas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HH-2853 in Natural Killer Cell Lymphomas report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. HH-2853 in Natural Killer Cell Lymphomas Drug Details: HH-2853...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tucidinostat in Hepatocellular Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tucidinostat in Hepatocellular Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tucidinostat in Hepatocellular Carcinoma Drug Details: Tucidinostat (Epidaza, Hiyasta) is a...
-
Product Insights
MRI Systems Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
MRI Systems Pipeline Market Report Overview Magnetic Resonance Imaging (MRI) generates clear and detailed images of internal organs and tissues using radiofrequency and a strong magnetic field. MRI is generally preferred for the diagnosis of brain and other neurological disorders. The 3T, 1.5T and 0.2-1.2T MRI systems have been tracked under this category. The MRI Systems pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report...